{
  "id": "cluster_0_doc4",
  "content": "Research note: ProPSP trial (NCT04599972) shows promise for combination therapy in supranuclear palsy. Participants require biweekly blood monitoring and monthly specialists visits. Current Gulf Coast enrollment includes 1 male patient aged 68 (H78456) with baseline UPDRS score of 52. Next assessment scheduled May 15th.",
  "metadata": {
    "format": "research_note"
  }
}